Summary:
A Randomized double blind placebo controlled parallel group study of the efficacy and safety of pregablin (BID) on subjects with post-traumatic peripheral neuropathic pain.
Qualified Participants Must:
• Be at least 18 years of age
•
Must agree to use a highly effective method of contraception, if of child bearing potential, throughout the study and for at least 28 days after the last dose of assigned
•
Have chronic peripheral neuropathic pain present for more than 6 months after a traumatic or surgical event per medical history (this may include, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury)
•
Have a score ≥4 on Weekly Pain Numeric Rating Scale (NRS) at Visit 1
•
Have completed at least 4 daily pain diaries during Screening during the 7 days during prior to Visit 2 with a mean pain score of ≥4 and ≤9 based on Daily Pain NRS to be eligible for randomization
•
Have had their implicated peripheral nerve(s) identified
Qualified Participants May Receive:
Study Medication, lab work, EKGs, hearing tests, and $50.00 for each completed visit for time and travel.